[Clinical evaluation of the use of teicoplanin for staphylococcal infections in immunocompetent and immunodepressed patients] NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[Clinical evaluation of the use of teicoplanin for staphylococcal infections in immunocompetent and immunodepressed patients]

Riv Eur Sci Med Farmacol. 1990 Dec;12(6):319-24. Unique Identifier : AIDSLINE MED/92073621
Catania S; Trinchieri V; Lanzalone CM; Causo T; Allegra C; Catania N; Cirelli A; Istituto Malattie Infettive, Universita La Sapienza, Roma.

Abstract: The authors have evaluated the efficacy and tolerance of teicoplanin against Gram-positive infections in 8 patients (four with endocarditis, one with cholangitis, one with purulent arthritis, one with gathered fistula and one with general pyoderma), arose both in the immunocompetent and immunodepressed subjects. All patients received IM teicoplanin at a dosage of 200-400 mg/die, according to the severity of the infectious process. Teicoplanin proved to be an effective and well-tolerated drug in the treatment of staphylococcus infections, both for immunocompetent and with serious deficit of the immune system subjects.
Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS/IMMUNOLOGY Adult Aged Antibiotics/*THERAPEUTIC USE English Abstract Female Glycopeptides/THERAPEUTIC USE Human *Immunocompromised Host Male Middle Age Staphylococcal Infections/COMPLICATIONS/*DRUG THERAPY/IMMUNOLOGY JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/KWDcomplications/immunologyadultagedantibiotics/KWDtherapeuticuseenglishabstractfemaleglycopeptides/therapeuticusehumanKWDimmunocompromisedhostmalemiddleagestaphylococcalinfections/complications/KWDdrugtherapy/immunologyjournalarticle
920330
M9230734

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .